| Sanofi-Aventis (Suisse) SA - Efluelda TIV 0.5 mL, suspension injectable en seringue pré-remplie |
| 69863 | | 01 | | Efluelda TIV 0.5 mL | | suspension injectable en seringue pré-remplie | | J07BB02 | | Influenza, gereinigtes Antigen | | 07.04.2025 | | |
|
| Zusammensetzung |
| haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022) 60 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Thailand/8/2022 (H3N2)-like: reassortant virus SAN-022 derived from A/California/122/2022) 60 µg, haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: derived from B/Michigan/01/2021 (Victoria lineage) wild type)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.96 mg. |
| Packungsbestandteile |
| suspension injectable en seringue pré-remplie | | | | | | Wirkstoffe | Stärke |
|---|
| Haemagglutininum Influenzae a (H1N1) (Virus Souche A/victoria/4897/2022 (H1N1)-Like: Reassortant Virus Ivr-238 Derived from A/victoria/4897/2022) | 60µg / 0.5ml | | Haemagglutininum Influenzae a (H3N2) (Virus Souche A/thailand/8/2022 (H3N2)-Like: Reassortant Virus San-022 Derived from A/california/122/2022) | 60µg / 0.5ml | | Haemagglutininum Influenzae b (Virus Souche B/austria/1359417/2021-Like: Derived from B/michigan/01/2021 (Victoria Lineage) wild Type)) | 60µg / 0.5ml |
| | | | Hilfsstoffe |
|---|
| Dinatrii Phosphas | | Natrii Chloridum | | Natrii Dihydrogenophosphas Anhydricus | | Octoxinolum-9 |
|
|
| Packungsnummer | Packungsgrösse | EFP | PP | Kat. | SL | In Refdata nicht gelistet |
|---|
| 001 | | PA | PA | B | | Nein | | 002 | 10 | PA | PA | B | | Nein |
|
